S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Best Bear Market Funds: Top 3 Investment Options to Consider
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Price, News & Analysis

$3.18
+0.33 (+11.58%)
(As of 03/27/2024 ET)
Today's Range
$2.81
$3.18
50-Day Range
$2.55
$3.49
52-Week Range
$1.11
$3.53
Volume
674,433 shs
Average Volume
301,155 shs
Market Capitalization
$204.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

GlycoMimetics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
214.5% Upside
$10.00 Price Target
Short Interest
Healthy
2.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.65mentions of GlycoMimetics in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.60) to ($0.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.42 out of 5 stars

Medical Sector

124th out of 939 stocks

Pharmaceutical Preparations Industry

48th out of 431 stocks

GLYC stock logo

About GlycoMimetics Stock (NASDAQ:GLYC)

GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

GLYC Stock Price History

GLYC Stock News Headlines

GlycoMimetics' (GLYC) "Buy" Rating Reaffirmed at HC Wainwright
Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Q4 2023 GlycoMimetics Inc Earnings Call
GlycoMimetics: Q4 Earnings Snapshot
Buy Friday, Sell Monday, No Exceptions
Every week traders grind it out Monday through Friday… But neglect trading Friday to Monday… Or… “over the weekend” As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today. It allows him to sidestep a lot of the midweek volatility. Yet, gives him the opportunity to target some of the markets biggest stock moves. Just recently, he posted a trade on Nordstrom… The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled.
GLYC Apr 2024 2.500 call
GLYC Apr 2024 2.500 put
GlycoMimetics Inc hosts conference call for investors
GLYC Apr 2024 5.000 call
Palatin Technologies Inc.
GlycoMimetics Inc GLYC
GlycoMimetics, Inc. (GKO.F)
See More Headlines
Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/03/2023
Today
3/27/2024
Next Earnings (Confirmed)
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GLYC
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$12.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+214.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-46,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$80,000.00
Book Value
$0.82 per share

Miscellaneous

Free Float
59,242,000
Market Cap
$204.95 million
Optionable
Optionable
Beta
2.19
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Harout Semerjian (Age 54)
    CEO, President & Director
    Comp: $1.1M
  • Ms. Rachel K. King (Age 65)
    Co-Founder & Director
    Comp: $226.43k
  • Mr. Brian M. Hahn (Age 50)
    Senior VP & CFO
    Comp: $748.27k
  • Ms. Stephanie R. Irish CPA (Age 53)
    Vice President of Accounting
  • Mr. Christian B. Dinneen-Long
    General Counsel & Company Secretary
  • Mr. Bruce Johnson (Age 56)
    Senior VP & Chief Commercial Officer
  • Dr. Edwin Rock M.D. (Age 63)
    Ph.D., Senior VP & Chief Medical Officer
  • Mr. Chinmaya Rath (Age 47)
    Senior VP & Chief Business Officer
  • Mr. Shantha Tyavanagimatt Ph.D.
    Senior Vice President of Technical Operations

GLYC Stock Analysis - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings
or view top-rated stocks.

What is GlycoMimetics' stock price target for 2024?

2 brokers have issued 1-year target prices for GlycoMimetics' stock. Their GLYC share price targets range from $8.00 to $12.00. On average, they predict the company's stock price to reach $10.00 in the next year. This suggests a possible upside of 214.5% from the stock's current price.
View analysts price targets for GLYC
or view top-rated stocks among Wall Street analysts.

How have GLYC shares performed in 2024?

GlycoMimetics' stock was trading at $2.36 at the beginning of 2024. Since then, GLYC shares have increased by 34.7% and is now trading at $3.18.
View the best growth stocks for 2024 here
.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) issued its quarterly earnings data on Friday, November, 3rd. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). During the same period in the prior year, the firm earned ($0.16) earnings per share.

What other stocks do shareholders of GlycoMimetics own?
Who are GlycoMimetics' major shareholders?

GlycoMimetics' stock is owned by many different institutional and retail investors. Top institutional investors include Goldman Sachs Group Inc. (1.43%), Goldman Sachs Group Inc. (1.43%), GSA Capital Partners LLP (0.31%), Bridgeway Capital Management LLC (0.31%), Northern Trust Corp (0.17%) and MJP Associates Inc. ADV (0.16%). Insiders that own company stock include Brian M Hahn, Bruce S Johnson, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews, Public Equities LP Invus and Scott D Sandell.
View institutional ownership trends
.

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GLYC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners